Sana Biotechnology Inc (SANA) Stock AnalysisSANASana Biotechnology Inc

Sana Biotechnology, Inc. is a biotechnology company focusing on utilizing engineered cells as medicines. It is engaged in developing ex vivo and in vivo cell engineering platforms to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including type 1 diabetes (T1D), oncology, and B cell mediated autoimmune diseases. It develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline products include SC451 and UP421. SC451 is its HIP-edited product candidate for the treatment of type 1 diabetes. SC451 is a pluripotent stem cell (PSC)-derived hypoimmune pancreatic islet cell product candidate for the treatment of diabetes, with an initial focus on T1D. Its ex vivo cell engineering platform is focused on engineering hypoimmune cells that engraft, function, and persist in patients by evading immune rejection. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Sana Biotechnology Inc is not a good buy right now due to its current price of $2.79, which is significantly lower than the analyst price target of $16, indicating potential upside. However, the stock has a troubling RSI of 33.64, suggesting it is oversold, and a negative forward P/E ratio of -3.94, indicating ongoing losses. Furthermore, the company has reported substantial net losses, with a net income of -49 million USD in Q4 2024 and a current ratio dropping to 1.38 in Q2 2026, raising concerns about liquidity.